Hyperemesis gravidarum: Difference between revisions
No edit summary |
|||
(2 intermediate revisions by one other user not shown) | |||
Line 2: | Line 2: | ||
*Simple [[nausea and vomiting]] affects 60-80% of patients during first 12wk of pregnancy | *Simple [[nausea and vomiting]] affects 60-80% of patients during first 12wk of pregnancy | ||
*Hyperemesis gravidarum only affects 0.3-2% of pregnancies<ref>Goodwin, TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am. 2008 Sep;35(3):401-17</ref> | *Hyperemesis gravidarum only affects 0.3-2% of pregnancies<ref>Goodwin, TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am. 2008 Sep;35(3):401-17</ref> | ||
*Hyperemesis gravidarum has been known to cause [[Wernicke's encephalopathy]]<ref>Kantor S, Prakash S, Chandwani J, Gokhale A, Sarma K, Albahrani MJ. Wernicke's encephalopathy following hyperemesis gravidarum. Indian J Crit Care Med. 2014;18(3):164–166. doi:10.4103/0972-5229.128706</ref><ref>Kotha VK, De Souza A. Wernicke's encephalopathy following Hyperemesis gravidarum. A report of three cases. Neuroradiol J. 2013;26(1):35–40. doi:10.1177/197140091302600106</ref> | *Hyperemesis gravidarum has (rarely) been known to cause [[Wernicke's encephalopathy]]<ref>Kantor S, Prakash S, Chandwani J, Gokhale A, Sarma K, Albahrani MJ. Wernicke's encephalopathy following hyperemesis gravidarum. Indian J Crit Care Med. 2014;18(3):164–166. doi:10.4103/0972-5229.128706</ref><ref>Kotha VK, De Souza A. Wernicke's encephalopathy following Hyperemesis gravidarum. A report of three cases. Neuroradiol J. 2013;26(1):35–40. doi:10.1177/197140091302600106</ref> | ||
==Clinical Features== | ==Clinical Features== | ||
* | *Defined as intractable [[vomiting]] with at least 1 of following: | ||
* | **Weight loss | ||
*''Note: [[Abdominal pain]] is highly unusual and should prompt consideration of a different diagnosis'' | **[[Hypovolemia|Volume depletion]] | ||
**[[Hypokalemia]] | |||
**[[Ketonemia]] | |||
''Note: [[Abdominal pain]] is highly unusual and should prompt consideration of a different diagnosis'' | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Line 14: | Line 18: | ||
==Evaluation== | ==Evaluation== | ||
===Workup=== | ===Workup=== | ||
*[[Urinalysis]] | *[[Urinalysis]] for ketones | ||
*Chemistry | |||
**May show signs of [[dehydration]], [[hypokalemia]] | |||
*CBC | *CBC | ||
==Management== | ==Management== | ||
===Rehydration=== | ===Rehydration=== | ||
*PO fluids if able to tolerate | *[[oral rehydration therapy|PO fluids]] if able to tolerate | ||
*IV fluid | *[[IVF|IV fluid repletion]] (use D5NS in the setting of ketonuria) | ||
===Antiemetics=== | ===Antiemetics=== | ||
Line 50: | Line 48: | ||
| [[Doxylamine]]||A | | [[Doxylamine]]||A | ||
|- | |- | ||
| [[Ondansetron]]|| | | [[Ondansetron]]||B | ||
|- | |- | ||
| [[Metoclopramide]]||B | | [[Metoclopramide]]||B | ||
Line 62: | Line 60: | ||
**Uncertain diagnosis | **Uncertain diagnosis | ||
**Intractable [[vomiting]] | **Intractable [[vomiting]] | ||
**Persistent ketonemia or [[electrolyte abnormalities]] after [[volume repletion]] | **Persistent [[ketonemia]] or [[electrolyte abnormalities]] after [[volume repletion]] | ||
**Weight loss >10% of pre-pregnancy weight | **Weight loss >10% of pre-pregnancy weight | ||
Revision as of 21:53, 12 January 2021
Background
- Simple nausea and vomiting affects 60-80% of patients during first 12wk of pregnancy
- Hyperemesis gravidarum only affects 0.3-2% of pregnancies[1]
- Hyperemesis gravidarum has (rarely) been known to cause Wernicke's encephalopathy[2][3]
Clinical Features
- Defined as intractable vomiting with at least 1 of following:
- Weight loss
- Volume depletion
- Hypokalemia
- Ketonemia
Note: Abdominal pain is highly unusual and should prompt consideration of a different diagnosis
Differential Diagnosis
Nausea and vomiting in pregnancy
- Hyperemesis gravidarum
- Gastroenteritis
- Biliary disease
- Ectopic pregnancy
- Gastroenteritis
- Pancreatitis
- Appendicitis
- Hepatitis
- Peptic ulcer disease
- Pyelonephritis
- Acute fatty liver of pregnancy
- HELLP syndrome
- Gestational trophoblastic disease (may present with intractable vomiting)
- Thyrotoxicosis (may present with intractable vomiting)
Evaluation
Workup
- Urinalysis for ketones
- Chemistry
- May show signs of dehydration, hypokalemia
- CBC
Management
Rehydration
- PO fluids if able to tolerate
- IV fluid repletion (use D5NS in the setting of ketonuria)
Antiemetics
ACOG recommends a stepwise approach to nausea and vomiting in pregnancy[4]
- Vitamin B6 10-25mg q6-8hrs
- ADD Doxylamine 12.5mg q6-8hrs
- ADD Promethazine 12.5-25mg q4hrs PO or PR
- ADD Dimenhydrinate 50mg q4-6hrs IV OR metoclopramide 5-10mg q8hrs IV OR promethazine 12.5-25mg q4hrs IV
- ADD Methylprednisolone 16mg q8hrs PO or IV for 3 days and taper to effective dose OR ondansteron 8mg (or 4mg) q12hrs IV
- If using ondansetron, reasonable to have a discussion about claimed risks of birth defects.
- First-trimester exposure to ondansetron was not associated with cardiac or congenital malformations but was associated with a small increased risk of oral clefts.[5]
Medication | Pregnancy Drug Class |
Vitamin B6 | A |
Dimenhydrinate | B |
Doxylamine | A |
Ondansetron | B |
Metoclopramide | B |
Promethazine | C |
Disposition
- Discharge if able to tolerate PO and ketonuria resolved
- Admit
- Uncertain diagnosis
- Intractable vomiting
- Persistent ketonemia or electrolyte abnormalities after volume repletion
- Weight loss >10% of pre-pregnancy weight
References
- ↑ Goodwin, TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am. 2008 Sep;35(3):401-17
- ↑ Kantor S, Prakash S, Chandwani J, Gokhale A, Sarma K, Albahrani MJ. Wernicke's encephalopathy following hyperemesis gravidarum. Indian J Crit Care Med. 2014;18(3):164–166. doi:10.4103/0972-5229.128706
- ↑ Kotha VK, De Souza A. Wernicke's encephalopathy following Hyperemesis gravidarum. A report of three cases. Neuroradiol J. 2013;26(1):35–40. doi:10.1177/197140091302600106
- ↑ Nausea and vomiting of pregnancy. ACOG Practice Bulletin No. 153. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2015; 126(3):e12-24
- ↑ Fejzo MS, et al. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016 Jul;62:87-91.